Esperion Update On Lead Cholestrol Drug Spooks Investors
This article was originally published in Scrip
Executive Summary
Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday.